Immune thrombocytopenia (ITP) trials in Czechia

In Czechia 9 Also abroad 118

9 of 9 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Where
Brno, Ostrava, Prague
Age
18 years and over
People
60 worldwide
Run by
Sanofi
See details and how to joinNCT07007962 · EU 2025-522070-36-00
Phase 3Taking people
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Where
Ostrava, Prague
Age
18 years and over
People
171 worldwide
Run by
Takeda
See details and how to joinNCT06722235 · EU 2024-514401-54-00
Phase 1Taking people
Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
Where
Prague
Age
18 years and over
People
78 worldwide
Run by
Chugai Pharmaceutical Co. Ltd.
See details and how to join2024-511346-39-00
Phase 3Taking people
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Where
Ostrava, Prague
Age
18 years and over
People
150 worldwide
Run by
Takeda
See details and how to joinNCT06948318 · EU 2025-521692-31-00
Phase 3Taking people
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
Where
Brno, Prague
Age
18 years to 70 years
People
40 worldwide
Run by
Kedrion S.p.A.
See details and how to joinNCT07059000 · EU 2023-507115-35-00
Phase 1Taking people
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Where
Praha 10 - Vinohrady
Age
18 years to 85 years
People
144 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00
Phase 1Enrolling by invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Where
Prague
Age
18 years to 85 years
People
144 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT06723106
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Where
Brno, Ostrava, Prague
Age
18 years and over
People
69 worldwide
Run by
argenx
See details and how to joinNCT06544499 · EU 2024-515451-38-00
Phase 2Taking people
Complex immunomodulatory therapy for patients with immune thrombocytopenia (T-MEM)
Where
Novy Hradec Kralove
Age
18 years and over
People
50
Run by
Fakultni Nemocnice Hradec Kralove
See details and how to join2023-505788-35-00